Level C· Early human research exploring benefitsProspective StudyPubMed

Unlocking the Cardioprotective Action of Human Amniotic Mesenchymal Stem Cells: A Review of the Current Documents.

Arefnezhd R., Moammer F., Ghaneimoghadam A., Khodabakhshian S., Safdari S., Nasiri R.

Prospective Study on Cardiovascular Disease, published in Health Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Health Sci Rep (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42441008
DOI
10.1002/hsr2.72685

Abstract (original English)

Cardiovascular diseases (CVDs), such as heart failure (HF), myocardial ischemic-reperfusion injury (MIRI), and myocardial infarction (MI), are defined as one of the most known causes of mortality and morbidity worldwide, responsible for 30% of global death rate. The etiologic factors for CVDs have not been exactly comprehended; however, a number of modifiable and nonmodifiable risk factors have been recognized, like smoking, physical activity, and the history of some diseases (e.g., hyperlipidemia, hypertension, and obesity). Although the current therapeutic approaches for these diseases, which are on the basis of conventional pharmacotherapy and surgery, have been largely effective in dwindling mortality and alleviating symptoms, the presence of serious side effects and injury to the different body organs and restricted clinical application are the main barriers of these methods. Therefore, there is an unmet need to recommend alternative and effective strategies with the minimum side effects for CVDs. Recently, mesenchymal stem cell (MSC)-based therapies have opened a new window to patients with diverse health problems. MSCs can be isolated from different sources, for example, adipose tissue, bone marrow, umbilical cord, amniotic membrane, and amniotic fluid, and have reflected remarkable pharmacological and biological abilities. An increasing body of evidence has paid special

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research